1997
Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs.
Lidow M, Elsworth J, Goldman-Rakic P. Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. Journal Of Pharmacology And Experimental Therapeutics 1997, 281: 597-603. PMID: 9103549.Peer-Reviewed Original ResearchConceptsChronic treatmentAntipsychotic drugsPrefrontal cortexReceptor antagonismDopamine receptorsD5 dopamine receptor mRNAD2 dopamine receptor antagonismD2 receptor antagonismDopamine receptor mRNAVehicle control groupTreatment of schizophreniaD1 classD5 dopamine receptorsDopamine receptor antagonismPrimate prefrontal cortexD5 mRNAsDopaminergic receptorsAntipsychotic medicationAntipsychotic efficacyD2 antagonistTherapeutic rangeAntipsychotic activityPharmacological spectrumReceptor mRNARibonuclease protection assays
1991
The D1 receptor antagonist, SCH 23390, induces signs of parkinsonism in African green monkeys
Lawrence M, Redmond D, Elsworth J, Taylor J, Roth R. The D1 receptor antagonist, SCH 23390, induces signs of parkinsonism in African green monkeys. Life Sciences 1991, 49: pl229-pl234. PMID: 1836030, DOI: 10.1016/0024-3205(91)90299-q.Peer-Reviewed Original ResearchConceptsSCH 23390African green monkeysD1 antagonistHealthy African green monkeysGreen monkeysParkinsonian side effectsD1 receptor antagonistPoverty of movementSigns of parkinsonismSelective D1 antagonistFull D1 agonistParkinsonian signsReceptor antagonistD1 agonistD1 receptorsSystemic administrationParkinson's diseasePsychiatric disordersSide effectsMotor changesClinical useParkinsonismAntagonistBlink rateMonkeys